Optimale medikamentöse Therapie bei Patienten nach akutem Koronarsyndrom

Abstract

Antithrombotic therapy and other secondary preventive measures such as lifestyle changes, lipid lowering and blood pressure control, along with coronary revascularization strategies, can markedly improve clinical outcomes in patients after an acute coronary syndrome. Current guideline-recommended secondary preventive measures in patients with a recent acute coronary syndrome event according to the European Society of Cardiology (ESC) are summarized in this review.

Bei Patienten nach akutem Koronarsyndrom sind – neben der koronaren Revaskularisation – eine antithrombotische Therapie, Lebensstil-Maßnahmen und eine optimale Kontrolle von Blutdruck und Lipidwerten von größter Bedeutung. Der vorliegende Beitrag fasst wichtige Empfehlungen aus den aktualisierten Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management von Patienten mit akutem Koronarsyndrom zusammen.

Schlüsselwörter

Akutes Koronarsyndrom - ST-Hebungsinfarkt - Nicht-ST-Hebungsinfarkt - anti-thrombotische Medikation - Sekundärprävention

Key words

acute coronary syndrome - ST segment elevation myocardial infarction - non-ST segment elevation myocardial infarction - anti-thrombotic therapy - secondary prevention

• Literatur

• 1 Townsend N, Nichols M, Scarborough P. et al. Cardiovascular disease in Europe--epidemiological update 2015. Eur Heart J 2015; 36: 2696-2705
• 2 Statistisches Bundesamt. Die 10 häufigsten Todesursachen. Im Internet: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Tabellen/HaeufigsteTodesursachen.html;jsessionid=6758DAF0A1DFB9A3B56A8791866EDA56.cae3 ; Stand: 30.1.2018
• 3 Roffi M, Patrono C, Collet JP. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315
• 4 Ibanez B, James S, Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2017; 39 (02) 119-177
• 5 Baigent C, Sudlow C, Collins R. Antithrombotic Trialists Collaboration. et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
• 6 Mehta SR, Bassand JP, Chrolavicius S. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. New Engl J Med 2010; 363: 930-942
• 7 Baigent C, Blackwell L, Collins R. Antithrombotic Trialists Collaboration. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
• 8 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2009; 361: 1045-1057
• 9 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2007; 357: 2001-2015
• 10 Montalescot G, Bolognese L, Dudek D. et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. New Eng J Med 2013; 369: 999-1010
• 11 Mehta SR, Yusuf S, Peters RJ. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533
• 12 Steinhubl SR, Berger PB, Mann JT. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420
• 13 Mauri L, Kereiakes DJ, Yeh RW. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. New Engl J Med 2014; 371: 2155-2166
• 14 Bonaca MP, Braunwald E, Sabatine MS. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New Engl J Med 2015; 373: 1274-1275
• 15 Udell JA, Bonaca MP, Collet JP. et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2016; 37: 390-399
• 16 Mega JL, Braunwald E, Wiviott SD. et al. Rivaroxaban in patients with a recent acute coronary syndrome. New Engl J Med 2012; 366: 9-19
• 17 Kereiakes DJ, Yeh RW, Massaro JM. et al. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol 2016; 67: 2492-2502
• 18 Valgimigli M, Bueno H, Byrne RA. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
• 19 Costa F, van Klaveren D, James S. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389: 1025-1034
• 20 Gorenek B, Kudaiberdieva G. Atrial fibrillation in acute ST-elevation myocardial infarction: clinical and prognostic features. Curr Cardiol Rev 2012; 8: 281-289
• 21 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962
• 22 Lip GY, Windecker S, Huber K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155-3179
• 23 Dewilde WJ, Oirbans T, Verheugt FW. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115
• 24 Angiolillo DJ, Goodman SG, Bhatt DL. et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv 2016; 9: e004395
• 25 Gibson CM, Mehran R, Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New Engl J Med 2016; 375: 2423-2434
• 26 Cannon CP, Bhatt DL, Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New Engl J Med 2017; 377 (16) 1513-1524
• 27 Sinning D, Landmesser U. ECS guidelines 2016 – dyslipidaemias. Herz 2016; 41: 671-676
• 28 Piepoli MF, Corra U, Dendale P. et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur Heart J Acute Cardiovasc Care 2017; 6: 299-310
• 29 Catapano AL, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999-3058
• 30 Cannon CP, Blazing MA, Giugliano RP. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New Engl J Med 2015; 372: 2387-2397
• 31 Sabatine MS, Giugliano RP, Keech AC. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New Engl J Med 2017; 376: 1713-1722
• 32 Nicholls SJ, Tuzcu EM, Sipahi I. et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508
• 33 Ray KK, Landmesser U, Leiter LA. et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New Engl J Med 2017; 376: 1430-1440
• 34 Sabatine MS, Giugliano RP, Wiviott SD. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New Engl J Med 2015; 372: 1500-1509
• 35 Robinson JG, Farnier M, Krempf M. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. New Engl J Med 2015; 372: 1489-1499
• 36 Giugliano RP, Pedersen TR, Park JG. et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 2017; 390: 1962-1971
• 37 Landmesser U, Chapman MJ, Farnier M. et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2017; 38: 2245-2255
• 38 Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219
• 39 Bohm M, Schumacher H, Teo KK. et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 2017; 389: 2226-2237